Vistagen Therapeutics Faces Class Action Lawsuit Over Securities Violations

Vistagen Therapeutics Faces Class Action Lawsuit for Securities Law Violations

Vistagen Therapeutics, Inc., a publicly traded company on NASDAQ under the symbol VTGN, has recently found itself at the center of a significant legal issue. Levi & Korsinsky, LLP, a well-known law firm specializing in securities litigation, has notified investors of a class action lawsuit against Vistagen due to alleged securities fraud. This legal action is directed at recovering losses suffered by investors during a specific period from April 1, 2024, to December 16, 2025.

Background of the Case

According to the complaint filed, Vistagen allegedly made misleading and materially false statements about its financial health and the results of its Phase 3 PALISADE-3 trial for fasedienol, an investigational drug aimed at treating social anxiety disorder. Investors were reportedly misled by the company’s positive statements regarding its clinical studies, which later proved to be unfounded.

On December 17, 2025, Vistagen published a press release indicating that the PALISADE-3 trial did not achieve the statistically significant improvement that they had previously claimed. In fact, the trial results demonstrated that there was no notable treatment difference between fasedienol and the placebo administered to patients, which led to a dramatic decline in the company's stock price. Following this announcement, shares plummeted from $4.36 to $0.86 within just one day, resulting in an over 80% drop in value.

Investor Impact and Legal Rights

This substantial decline has prompted affected investors to seek legal recourse. If you've experienced losses attributed to this period, you may be eligible to participate in the class action suit. Investors have until March 16, 2026, to file a request with the court to have themselves appointed as lead plaintiffs. Importantly, participation in any potential recovery would not impose any financial obligations on the investors, as there are no out-of-pocket costs associated with joining the lawsuit.

Joseph E. Levi, the lead attorney handling the case, emphasizes that the firm has a distinguished history of advocating on behalf of shareholders and has achieved favorable resolutions for many clients in the past. With a record spanning over two decades and a team of experienced attorneys, Levi & Korsinsky has established its reputation within complex securities litigation.

Moving Forward

As the legal process unfolds, investors are encouraged to stay informed about their rights and options following the lawsuit's announcement. Those who believe they were negatively affected by the practices of Vistagen Therapeutics during the cited time frame should consider reaching out to Levi & Korsinsky to discuss their situation further.

To get additional information or to submit your claim, interested parties can visit their website or contact the firm directly via phone or email. The outreach of this lawsuit showcases the ongoing scrutiny that public companies face with their disclosures and the importance of transparency in the biotech and pharmaceutical sectors.

Conclusion

The situation surrounding Vistagen Therapeutics underscores critical issues in corporate governance and investor protection. As more details emerge regarding the class action suit, it serves as a reminder for investors to be vigilant about the disclosures made by companies in which they invest. The outcome of this case could have significant implications not only for Vistagen but also for the broader industry as it grapples with similar challenges in investor relations and regulatory compliance.